What are the best treatments for Bladder Cancer?

The treatment of bladder cancer is highly personalized, typically involving surgery, intravesical therapy, or systemic chemotherapy depending on whether the disease is muscle-invasive or non-muscle-invasive. A multidisciplinary team approach is essential to determine the most effective strategy based on the stage, grade, and molecular characteristics of the individual's bladder cancer.

What are the primary treatment options for bladder cancer?

Treatment for bladder cancer is categorized by the depth of tumor invasion. For non-muscle-invasive bladder cancer, the standard of care is Transurethral Resection of Bladder Tumor (TURBT) followed by intravesical therapy. For muscle-invasive bladder cancer, treatment often requires radical cystectomy (surgical removal of the bladder) or a combination of chemotherapy and radiation therapy to preserve the organ. The choice depends on the specific pathology of the bladder cancer cells.

What medications are commonly used?

Pharmacological management of bladder cancer includes both localized and systemic approaches:

• Intravesical Immunotherapy: Bacillus Calmette-Guérin (BCG) is the gold standard for high-risk non-muscle-invasive bladder cancer.


• Intravesical Chemotherapy: Medications such as mitomycin (Mutamycin) or gemcitabine (Gemzar) may be instilled directly into the bladder.


• Systemic Chemotherapy: Cisplatin and gemcitabine are frequently used as first-line intravenous treatments for advanced bladder cancer.


• Immunotherapy: Checkpoint inhibitors like pembrolizumab (Keytruda) or atezolizumab (Tecentriq) are approved for specific advanced cases.

Which specialists should be on my care team?

Managing bladder cancer effectively requires a multidisciplinary team. Key specialists include a urologic oncologist, a medical oncologist, a radiation oncologist, and a specialized nurse navigator. Our 68 members at DiseaseMaps.org often emphasize the importance of involving a pelvic floor physical therapist to assist with recovery after surgery or radiation.

Are there emerging treatments?

Research into bladder cancer is rapidly evolving, with ongoing clinical trials investigating antibody-drug conjugates (ADCs) like enfortumab vedotin (Padcev) and targeted therapies for patients with specific genetic mutations, such as FGFR alterations. Always consult your oncology team regarding current clinical trials available for your specific stage of bladder cancer.

Next steps

• Consult a board-certified urologic oncologist to discuss your specific staging.


• Request a pathology review to identify potential genetic markers for targeted therapy.


• Connect with the 68 members of our bladder cancer community at DiseaseMaps.org for peer support.


• Review clinical trial eligibility through the National Cancer Institute (NCI) database.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your healthcare provider for personalized treatment decisions.

References

• National Cancer Institute (NCI) - Bladder Cancer Treatment (PDQ®)


• American Cancer Society - Key Statistics and Treatment Guidelines for Bladder Cancer


• Bladder Cancer Advocacy Network (BCAN)


• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines